- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Timing good for 2-in-1 biotech drugs
July 5, 2011
J.K. WallEli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the
world’s most successful biotech medicines, which are about to see their patents expire.
MoreR&D spending soars above value of new drugs
July 5, 2011
J.K. WallTo understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending
$57 billion more per year on research and development than the value of the products it has been launching. That’s a
problem.
MoreLilly asks judge to reject U.K. Zyprexa case
July 5, 2011
Bloomberg NewsEli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge
in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
MoreLilly plans 10 drugs in final-stage trials by year's end
June 30, 2011
Bloomberg NewsLilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s
disease, up from seven in 2005, the Indianapolis-based company said Thursday.
MoreLilly plans more investment in two-in-one drugs
June 28, 2011
J.K. WallIndianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act
like two medicines in one. Lilly plans to add more scientists to back the effort.
MoreZyprexa appeal rejected by Supreme Court
June 27, 2011
Bloomberg NewsThe U.S. Supreme Court has refused to revive a bid to press a $6.8 billion class-action suit against Eli Lilly and Co. over
the marketing of Zyprexa, the company’s schizophrenia treatment.
MoreLilly, partner find no Bydureon effect on heart rhythm
June 27, 2011
Bloomberg NewsEli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence
that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
MoreLilly diabetes pill recommended for EU approval
June 24, 2011
Bloomberg NewsEli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval
in Europe, putting the drug on track to enter the region’s market this year.
MoreLilly CEO: Immigration, tax laws slow innovation
June 23, 2011
Bloomberg NewsThe U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly
& Co. CEO John Lechleiter plans to tell a technology conference Thursday.
MoreEU approves Lilly's weekly diabetes drug Bydureon
June 21, 2011
Associated PressEuropean Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug
said Tuesday.
MoreLilly enters collaboration deal with Swiss company
June 9, 2011
Associated PressDrugmaker Eli Lilly and Co. has signed a deal with Swiss company Synthes Inc. to co-promote the bone drug Forteo and develop
other potential orthopedic treatments.
MoreLilly wins ruling in dispute with Amylin over diabetes drugs
June 8, 2011
Bloomberg NewsEli Lilly and Co. won a ruling in a lawsuit brought by Amylin Pharmaceuticals Inc., which wants to prevent Lilly from using
the same people to sell Amylin’s diabetes drug and that of a competitor.
MoreDrug industry outlook negative through 2012, Moody’s says
June 8, 2011
Bloomberg NewsEarnings growth will continue to slow in 2011 for most of the industry’s biggest companies, analyst predicts.
MoreRoche wins as high court limits university patent rights
June 6, 2011
Bloomberg NewsMonday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based
Eli Lilly and Co. was among the companies that supported Roche.
MoreLilly licenses Xigris rights to new biotech firm
May 23, 2011
J.K. WallEli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created
local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
MoreGrowth in drug spending to slow as generics rise
May 18, 2011
Bloomberg NewsThe annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic
medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical
firms like Eli Lilly and Co. are facing.
MoreAmylin sues Lilly over drug development deal
May 16, 2011
Associated PressAmylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking
their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell
a competing product.
MoreEli Lilly's slumbering stock finally shows signs of life
May 14, 2011
Greg AndrewsIs it finally time to get some growth again out of a stock that since its debut on the public market 59 years ago has minted
thousands of millionaires?
MoreLilly drug to detect Alzheimer’s criticized by consumer group
May 11, 2011
Bloomberg NewsEli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain,
shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
MoreTwo wins to bring Lilly modest sales
May 9, 2011
J.K. WallFinally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a
new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties
for the Indianapolis-based drugmaker.
MoreEli Lilly pledges $2.5 million to Mind Trust
May 5, 2011
J.K. WallEli Lilly and Co. plans to give $2.5 million toward a new fundraising campaign by the Mind Trust, an Indianapolis-based education
reform group.
MoreFDA OKs new diabetes pill from Lilly, Boehringer
May 2, 2011
IBJ Staff and Associated PressThe Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients
who can't control their blood sugar with older medicines.
MoreLilly teams with Medtronic on Parkinson's treatment
April 26, 2011
J.K. WallEli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients'
brains with an experimental drug for Parkinson’s disease.
MoreLilly shareholders fail to remove anti-takeover measures
April 18, 2011
J.K. WallA proposal that would have weakened Eli Lilly and Co.’s defenses against an unwanted takeover failed to pass Monday
despite a large majority of shareholders voting to remove those barriers for the second straight year.
MoreAnalysts demand news on next Lilly blockbuster
April 18, 2011
J.K. WallEli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not
connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just
want to know when the next blockbuster will be coming.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
See, I told u Indyman and Dipsicle....this 8 days is overkill. It's barely worth a weekend....great job Tony George! Your dream has been fulfilled....he fans want the I r l back. Thats how good it was.....and that sucked.
I have been in training for a short time now but right off I can see that safety and quality are the number one issues, my experience as of late has been a positive one, the employees along with Jeff the plant manager and the operation supervisor as well as the engineers are a highly motivated group of people, what an asset for the area to have and for company's in need of a quality metal products.
Pimlico
While I understand the severity of their actions as well as everyones eagerness to hold them responsible for thier lost funds, these gentlemen did know how to make money. Dispite thier poor decisions over the ownership of Fair they had made several wise investments which paid them greatly. This proves they do have the potential to rebuild so they can repay. I do not feel they should live the life of luxuary but given an opportunity could they find ways of repaying the debts? They are doing nothing now but being a burden on tax payers. Just a thought!!!!!
You guys have some "interesting" comments to say the least. I hope you will call in and share those opinions starting June 1. I'm looking forward to having you on the air.